Immunogene therapy against mouse leukemia using B7 molecules

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 144-150

  Takahashi, Tsuyoshi ^a   Hirano, Naoto ^a   Takahashi, Tokiharu ^a   Chiba, Shigeru ^a   Yazaki, Yoshio ^a   Hirai, Hisamaru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

B7 molecules; Gene therapy; Leukemia

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSDUCTION; LYMPHOCYTE DEPLETION; MOUSE; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALIA;

EID: 0033961965     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700099     Document Type: Article

References (31)

1. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion vs. functional clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
2. Schwartz RH. Acquisition of immunological self-tolerance. Cell. 1989;57:1073-1081.
3. Yokochi T, Holly RD, Clark EA. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphoma. J Immunol. 1982;128:823-827.
4. Freeman GJ, Freedman AS, Segil JM, et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143: 2714-2722.
5. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76-79.
6. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7:445-450.
7. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71: 1093-1102.
8. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
9. Tzyy-Choou WU, Huang AY, Jaffee EM, et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995;182:1415-1421.
10. Yang G, Hellstrom KE, Hellstrom I, et al. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol. 1995;154:2794-2800.
11. + T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996;156:465-472.
12. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996;156:1126-1131.
13. Martin-Fontecha A, Cavallo F, Bellone M, et al. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol. 1996;26:1851-1859.
14. Muller AJ, Young JC, Pendergast AM, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991;11:1785-1792.
15. Yoshida K, Nemoto K, Nishimura M, et al. Exacerbating factors of radiation-induced myeloid leukemogenesis. Leukemia Res. 1993;17:437-440.
16. 1: reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981;127:34-38.
17. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
18. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994; 1:793-801.
19. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995;80:707-718.
20. Lenschow DJ, Ho SC, Satter H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995;181:1145-1155.
21. Eck SC, Chang D, Wells AD, et al. Differential downregulation of CD28 by B7-1 and B7-2 engagement. Transplantation. 1997;64:1497-1499.
22. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994;153:421-428.
23. Hirano N, Takahashi T, Takahashi T, et al. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CDSO)-transduced leukemic cells. Hum Gene Ther. 1997;8:1375-1384.
24. Huang AY, Bruce AT, Pardoll DM, et al. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med. 1996;183:769-776.
25. Geldhof AB, Raes G, Bakkus M, et al. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res. 1995; 55:2730-2733.
26. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity. 1996;5:311-317.
27. Matulonis U, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995;85:2507-2515.
28. Dunussi-Joannopourls K, Weinstein HJ, Nickerson PW, et al. Irradiated B7-1-transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood. 1996;87:2938-2946.
29. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
30. Cavallo F, Martin-Fontecha A, Bellone M, et al. Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol. 1995;25:1154-1162.
31. Hirano N, Takahashi T, Takahashi T, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168-1176.